$211 Million is the total value of Tamarack Advisers, LP's 49 reported holdings in Q1 2022. The portfolio turnover from Q4 2021 to Q1 2022 was 100.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| Exit | RIGL US 01/21/22 C10call | $0 | – | -5,705 | -100.0% | -0.01% | – | |
| Exit | VTRS US 01/21/22 C15call | $0 | – | -10,000 | -100.0% | -0.02% | – | |
| Exit | CM LIFE SCIENCES II -CW27warrant | $0 | – | -20,000 | -100.0% | -0.03% | – | |
| PRGO | Exit | PERRIGO CO PLCequity | $0 | – | -10,000 | -100.0% | -0.16% | – |
| Exit | IWM US 02/18/22 P215put | $0 | – | -1,000 | -100.0% | -0.18% | – | |
| Exit | TDOC US 01/21/22 P115put | $0 | – | -250 | -100.0% | -0.24% | – | |
| GTBIF | Exit | GREEN THUMB INDUSTRIES INCequity | $0 | – | -75,000 | -100.0% | -0.68% | – |
| ITGR | Exit | INTEGER HOLDINGS CORPequity | $0 | – | -25,000 | -100.0% | -0.88% | – |
| XBI | Exit | SPDR S&P BIOTECH ETFexchange traded fund | $0 | – | -25,000 | -100.0% | -1.15% | – |
| JAZZ | Exit | JAZZ PHARMACEUTICALS PLCequity | $0 | – | -25,000 | -100.0% | -1.31% | – |
| UTHR | Exit | UNITED THERAPEUTICS CORPequity | $0 | – | -15,000 | -100.0% | -1.33% | – |
| BAX | Exit | BAXTER INTERNATIONAL INCequity | $0 | – | -50,000 | -100.0% | -1.76% | – |
| SMG | Exit | SCOTTS MIRACLE-GRO COequity | $0 | – | -30,000 | -100.0% | -1.99% | – |
| MCK | Exit | MCKESSON CORPequity | $0 | – | -20,000 | -100.0% | -2.04% | – |
| ELY | Exit | CALLAWAY GOLF COMPANYequity | $0 | – | -200,000 | -100.0% | -2.26% | – |
| STRM | Exit | STREAMLINE HEALTH SOLUTIONSequity | $0 | – | -4,930,882 | -100.0% | -3.02% | – |
| BMRN | Exit | BIOMARIN PHARMACEUTICAL INCequity | $0 | – | -90,000 | -100.0% | -3.27% | – |
| HUM | Exit | HUMANA INCequity | $0 | – | -20,000 | -100.0% | -3.81% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2022-05-11
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| VERADIGM ORD | 32 | Q3 2023 | 13.9% |
| STREAMLINE HEALTH SOLUTIONS ORD | 30 | Q3 2023 | 4.0% |
| ATRICURE ORD | 29 | Q3 2023 | 7.6% |
| PACIRA PHARMACEUTICALS INC | 27 | Q1 2023 | 12.1% |
| LANTHEUS HOLDINGS ORD | 25 | Q4 2022 | 9.6% |
| MEDTRONIC PLC | 21 | Q1 2022 | 12.7% |
| RIGEL PHARMACEUTICALS ORD | 21 | Q2 2023 | 8.0% |
| BIO RAD LABORATORIES CL A ORD | 19 | Q2 2023 | 10.0% |
| HOLOGIC INC | 17 | Q1 2022 | 6.5% |
| SPY US 10/21/16 P210 | 17 | Q3 2023 | 41.5% |
View Tamarack Advisers, LP's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| STREAMLINE HEALTH SOLUTIONS INC. | June 22, 2023 | 5,514,515 | 9.4% |
| IVERIC bio, Inc. | February 16, 2021 | 850,000 | 0.1% |
| Correvio Pharma Corp. | February 14, 2020 | 2,500,000 | 4.9% |
| OBALON THERAPEUTICS INC | February 14, 2020 | ? | ? |
| Correvio Pharma Corp. | February 15, 2019 | ? | ? |
| Corium International, Inc. | February 15, 2017 | 737,242 | 3.3% |
| ENDOLOGIX INC /DE/Sold out | February 15, 2017 | 0 | 0.0% |
| Imprivata IncSold out | February 15, 2017 | 0 | 0.0% |
View Tamarack Advisers, LP's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-02-09 |
| 13F-HR | 2023-11-16 |
| 13F-HR | 2023-08-10 |
| SC 13D/A | 2023-06-22 |
| 13F-HR | 2023-05-11 |
| 13F-HR | 2023-02-13 |
| SC 13D/A | 2022-12-01 |
| 13F-HR | 2022-11-15 |
| 13F-HR | 2022-08-16 |
| 13F-HR | 2022-05-11 |
View Tamarack Advisers, LP's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.